.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Eletriptan hydrobromide - Generic Drug Details

« Back to Dashboard
Eletriptan hydrobromide is the generic ingredient in one branded drug marketed by Pfizer Ireland and is included in one NDA. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has one hundred and forty-seven patent family members in forty-six countries.

There are eleven drug master file entries for eletriptan hydrobromide. Five suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for Generic Name: eletriptan hydrobromide

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list11
Suppliers / Packaging: see list5
Drug Prices:see low prices

Pharmacology for Ingredient: eletriptan hydrobromide

Tentative approvals for ELETRIPTAN HYDROBROMIDE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL20MG
<disabled><disabled>TABLET; ORAL40MG
<disabled><disabled>TABLET; ORALEQ 20MG BASE
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002RXNo6,110,940► subscribe ► subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-002Dec 26, 2002RXYes5,545,644► subscribeYY ► subscribe
Pfizer Ireland
RELPAX
eletriptan hydrobromide
TABLET;ORAL021016-001Dec 26, 2002RXNo5,545,644► subscribeYY ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: eletriptan hydrobromide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,380,226 Salts of an anti-migraine indole derivatives► subscribe
5,559,129 Indole derivatives► subscribe
5,559,246 Indole derivatives► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: eletriptan hydrobromide

Country Document Number Estimated Expiration
Spain2112650► subscribe
Finland105812► subscribe
Poland170330► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELETRIPTAN HYDROBROMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/023United Kingdom► subscribePRODUCT NAME: ELETRIPTAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE HYDROBROMIDE SALT; REGISTERED: CH 55218 01 20001214; CH 52218 02 20001214; CH 52218 03 20001214; UK PL 00057/0452 20010212; UK PL 00057/0453 20010212; UK PL 00057/0454 20010212
C0013France► subscribePRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214
0592438/01Switzerland► subscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc